Mucinous ovarian cancer

International Journal of Gynecological Cancer

Volumn 18, Issue 2, 2008, Pages 209-214

  Harrison, M L ^a   Jameson, C ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Epithelial ovarian cancer; Molecular studies; Mucinous; Pathology

Indexed keywords

CA 125 ANTIGEN; CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; TUMOR MARKER;

CANCER CHEMOTHERAPY; CLINICAL FEATURE; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MOLECULAR GENETICS; MUCINOUS CARCINOMA; OVARY CANCER; OVARY METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; VISCERAL METASTASIS;

ADENOCARCINOMA, MUCINOUS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 40549098128     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01022.x     Document Type: Review

References (40)

1. McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002 84 : 399 403.
2. Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001 357 : 176 82.
3. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002 360 : 505 15.
4. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas. A clinicopathologic study of 49 cases with long term follow-up. Am J Surg Pathol 1998 22 : 1449 62.
5. Lee K, Scully RE. Mucinous tumors of the ovary. A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with "pseudomyxoma peritonei". Am J Surg Pathol 2000 24 : 1447 64.
6. Rodríguez IM, Prat J. Mucinous tumors of the ovary. A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002 26 : 139 52.
7. Kristensen GB, Kildal W, Abeler VM et al. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 2003 14 : 1494 500.
8. Guerrieri C, Hogberg T, Wingren S et al. Mucinous borderline and malignant tumours of the ovary. A clinicopathologic and DNA ploidy study of 92 cases. Cancer 1994 74 : 2329 40.
9. Prat J, Young RH, Scully RE. Ovarian mucinous tumors with foci of anaplastic carcinoma. Cancer 1982 50 : 300 4.
10. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003 27 : 985 93.
11. Khunamornpong S, Suprasert P, Pojchamarnwiputh S et al. Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol 2006 101 : 152 7.
12. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 2003 27 : 281 92.
13. Ji H, Isacson C, Seidman J et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002 21 : 391 400.
14. Park SY, Kim HS, Hong EK et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002 33 : 1078 85.
15. Vang R, Gown AM, Barry TS et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006 30 : 1130 9.
16. Berezowski K, Stastny JK, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in colonic and ovarian carcinoma. Mod Pathol 1996 9 : 426 9.
17. DeCostanzo DC, Elias JM, Chumas JC. Necrosis in 84 ovarian carcinomas: a morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen. Int J Gynecol Pathol 1997 16 : 245 9.
18. Vang R, Gown AM, Barry TS et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006 19 : 97 105.
19. Pieretti M, Hopenhayn-Rich C, Khattar NH et al. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002 20 : 11 23.
20. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003 202 : 97 9.
21. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001 85 : 692 6.
22. Lohr M, Kloppel G, Maisonneuve P et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005 7 : 17 23.
23. Puls LE, Powell DE, DePriest PD et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992 47 : 53 7.
24. Cuatrecasas M, Villanueva A, Matias-Guiu X et al. K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer 1997 79 : 1581 6.
25. Garrett AP, Lee KR, Colliti CR et al. k-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001 20 : 244 51.
26. Wamunyokoli FW, Bonome T, Lee J et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 2006 12 : 690 700.
27. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001 68 : 700 10.
28. Yedema C, Kenemans P, Wobbes T et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992 13 : 18 26.
29. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004 22 : 1040 4.
30. Pectasides D, Fountzilas G, Aravantinos G et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005 97 : 436 41.
31. Tholander B, Taube A, Lindgren A et al. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 1990 39 : 26 33.
32. Pisano C, Greggi S, Tambaro R et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Anticancer Res 2005 25 : 3501 5.
33. Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003 95 : 105 12.
34. Shimizu Y, Umezawa S, Hasumi K. A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singap 1998 27 : 650 6.
35. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 2004 95 : 165 72.
36. Sundar S, Symonds RP, Decatris MP et al. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol 2004 94 : 502 8.
37. Burger RA, Sill M, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study [abstract]. Proc Am Soc Clin Oncol 2005 23 : S16. Abstract 5009.
38. Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2006 24 : S18. Abstract 5006.
39. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 42.
40. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. Proc Am Soc Clin Oncol 2005 23 : S16. Abstract 2.